tiprankstipranks
Cognition Therapeutics (CGTX)
NASDAQ:CGTX
US Market
CGTX
Cognition Therapeutics
RESEARCH TOOLSreports

Cognition Therapeutics (CGTX) Stock News & Sentiment

618 Followers
Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications
Premium
Ratings
Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications
15d ago
CGTX
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
Premium
Company Announcements
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
16d ago
8K
CGTX
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
Premium
Ratings
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
1M ago
CGTX
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
Premium
Company Announcements
Cognition Therapeutics Advances Zervimesine for DLB Psychosis
1M ago
8K
CGTX
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial
Premium
Company Announcements
Cognition Therapeutics Advances Zervimesine Toward Phase 2b Trial
2M ago
8K
CGTX
Cognition Therapeutics Launches New $75M ATM Offering
Premium
Company Announcements
Cognition Therapeutics Launches New $75M ATM Offering
4M ago
8K
CGTX
Cognition Therapeutics’ Promising Advances in Dementia Treatment Justify Buy Rating
Premium
Ratings
Cognition Therapeutics’ Promising Advances in Dementia Treatment Justify Buy Rating
4M ago
CGTX
More CGTX News >

CGTX News on the Web

Cognition Therapeutics Charts New Course with Late-Stage Plans for Zervimesine in DLB Psychosis and Alzheimer’s
Market Chameleon
Neutral
Cognition Therapeutics: Buy Rating Backed by Zervimesine Pivotal Path and Risk‑Adjusted Upside Across Neurodegenerative Indications
TipRanks News
Bullish
Cognition Therapeutics Inc (CGTX) Q4 2025 Earnings Call Highlights: Promising Developments in ...
GuruFocus News
Bullish
Q4 2025 Cognition Therapeutics Inc Earnings Call Transcript
GuruFocus News
Neutral
Cognition Therapeutics (CGTX) Beats EPS Expectations, Secures Strong Cash Position
GuruFocus News
Bullish
Cognition Therapeutics Highlights 2025 Results, Zervimesine Progress
TipRanks News
Neutral
Cognition Therapeutics’ zervimesine shows eficacy in dementia trial
TipRanks News
Bullish
Cognition Therapeutics: FDA-Aligned Late-Stage Path for Zervimesine in DLB Psychosis and Alzheimer’s Supports Reiterated Buy Rating
TipRanks News
Bullish

News Score - Last 7 Days

Not enough data to generate a sentiment score
Media Buzz
This Week0 articles
Weekly Average0 articles
News Sentiment
Currently, no data available
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is CGTX’s Media Buzz Sentiment?
Currently, no data Available
What is CGTX’s weekly average amount of articles?
Currently, no data Available
What is CGTX’s News Sentiment?
Currently, no data Available
Healthcare Stocks that are Trending in the News
AORTArtivion
NBIXNeurocrine
STAAStaar Surgical
SLPSimulations Plus
OWLTOwlet
Showing the stocks with the most bullish news sentiment over the past week